Kwality Pharmaceuticals zooms on getting nod for Leuprorelin Acetate 11.25 mg vial powder & solvent for injectable suspension
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Kwality Pharmaceuticals is currently trading at Rs. 941.05, up by 44.80 points or 5.00% from its previous closing of Rs. 896.25 on the BSE.
The scrip opened at Rs. 914.00 and has touched a high and low of Rs. 941.05 and Rs. 860.00 respectively. So far 18908 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 961.15 on 04-Nov-2024 and a 52 week low of Rs. 331.10 on 07-Nov-2023.
Last one week high and low of the scrip stood at Rs. 941.05 and Rs. 860.00 respectively. The current market cap of the company is Rs. 960.84 crore.
The promoters holding in the company stood at 54.83%, while Institutions and Non-Institutions held 0.02% and 45.15% respectively.
Kwality Pharmaceuticals has successfully filed and got the approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension as a site variation in Greece, marking its entry into the European Markets. Kwality Pharma will supply the first three validation batches in December and after complete Quality Control Analysis, will start regular supplies from January 2025 onwards.
This strategic CDMO arrangement is projected to generate around $3 million of yearly sales, with distribution set to begin in the 4th quarter of this fiscal year. Furthermore, the company has plans to add remaining strengths of the same in the product portfolio with the same buyer as well. This marks a pivotal step in its strategy to introduce products in highly regulated markets.
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.
